212 related articles for article (PubMed ID: 25297748)
1. [Treatment strategy for myeloproliferative neoplasms].
Yoshimoto G; Miyamoto T
Rinsho Ketsueki; 2014 Oct; 55(10):1841-52. PubMed ID: 25297748
[No Abstract] [Full Text] [Related]
2. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.
Stein BL; Gotlib J; Arcasoy M; Nguyen MH; Shah N; Moliterno A; Jamieson C; Pollyea DA; Scott B; Wadleigh M; Levine R; Komrokji R; Klisovic R; Gundabolu K; Kropf P; Wetzler M; Oh ST; Ribeiro R; Paschal R; Mohan S; Podoltsev N; Prchal J; Talpaz M; Snyder D; Verstovsek S; Mesa RA
J Natl Compr Canc Netw; 2015 Apr; 13(4):424-34. PubMed ID: 25870379
[TBL] [Abstract][Full Text] [Related]
3. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
Mesa R; Jamieson C; Bhatia R; Deininger MW; Gerds AT; Gojo I; Gotlib J; Gundabolu K; Hobbs G; Klisovic RB; Kropf P; Mohan SR; Oh S; Padron E; Podoltsev N; Pollyea DA; Rampal R; Rein LA; Scott B; Snyder DS; Stein BL; Verstovsek S; Wadleigh M; Wang ES; Bergman MA; Gregory KM; Sundar H
J Natl Compr Canc Netw; 2016 Dec; 14(12):1572-1611. PubMed ID: 27956542
[TBL] [Abstract][Full Text] [Related]
4. Searching for CALRity in myeloproliferative neoplasms.
Cook JR
Am J Clin Pathol; 2015 May; 143(5):617-9. PubMed ID: 25873492
[No Abstract] [Full Text] [Related]
5. Myeloproliferative neoplasms.
Publicover A; Medd P
Clin Med (Lond); 2013 Apr; 13(2):188-92. PubMed ID: 23681871
[TBL] [Abstract][Full Text] [Related]
6. [Complex molecular genetic algorithm in the diagnosis of myeloproliferative neoplasms].
Krähling T; Balassa K; Meggyesi N; Bors A; Csomor J; Bátai Á; Halm G; Egyed M; Fekete S; Reményi P; Masszi T; Tordai A; Andrikovics H
Orv Hetil; 2014 Dec; 155(52):2074-81. PubMed ID: 25528320
[TBL] [Abstract][Full Text] [Related]
7. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
8. Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome.
Asp J; Andréasson B; Hansson U; Wasslavik C; Abelsson J; Johansson P; Palmqvist L
Haematologica; 2016 Apr; 101(4):e129-32. PubMed ID: 26768689
[No Abstract] [Full Text] [Related]
9. Chronic myeloproliferative neoplasms in the elderly.
Maffioli M; Orlandi E; Passamonti F
Eur J Intern Med; 2018 Dec; 58():33-42. PubMed ID: 29793825
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.
Tefferi A; Guglielmelli P; Larson DR; Finke C; Wassie EA; Pieri L; Gangat N; Fjerza R; Belachew AA; Lasho TL; Ketterling RP; Hanson CA; Rambaldi A; Finazzi G; Thiele J; Barbui T; Pardanani A; Vannucchi AM
Blood; 2014 Oct; 124(16):2507-13; quiz 2615. PubMed ID: 25037629
[TBL] [Abstract][Full Text] [Related]
11. Molecular genetic evaluation of myeloproliferative neoplasms.
Azzato EM; Bagg A
Int J Lab Hematol; 2015 May; 37 Suppl 1():61-71. PubMed ID: 25976962
[TBL] [Abstract][Full Text] [Related]
12. [Management strategy for BCR-ABL negative myeloproliferative neoplasms].
Gotoh A; Komatsu N
Rinsho Ketsueki; 2014 Jan; 55(1):56-65. PubMed ID: 24492037
[No Abstract] [Full Text] [Related]
13. Life, genes, and death in Ph- MPNs.
Silver RT
Blood; 2014 Oct; 124(16):2471-2. PubMed ID: 25323682
[TBL] [Abstract][Full Text] [Related]
14. Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Zeeh FC; Meyer SC
Hamostaseologie; 2021 Jun; 41(3):197-205. PubMed ID: 34192778
[TBL] [Abstract][Full Text] [Related]
15. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
16. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
17. Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.
Andrikovics H; Krahling T; Balassa K; Halm G; Bors A; Koszarska M; Batai A; Dolgos J; Csomor J; Egyed M; Sipos A; Remenyi P; Tordai A; Masszi T
Haematologica; 2014 Jul; 99(7):1184-90. PubMed ID: 24895336
[TBL] [Abstract][Full Text] [Related]
18. Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions.
Shammo JM; Stein BL
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):552-560. PubMed ID: 27913528
[TBL] [Abstract][Full Text] [Related]
19. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.
Mejía-Ochoa M; Acevedo Toro PA; Cardona-Arias JA
BMC Cancer; 2019 Jun; 19(1):590. PubMed ID: 31208359
[TBL] [Abstract][Full Text] [Related]
20. Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture.
Tefferi A
Leuk Res; 2012 Dec; 36(12):1481-9. PubMed ID: 22917768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]